Compare Schwab US Dividend Equity ETF (SCHD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Zoetis Inc — how do they compare? Schwab US Dividend Equity ETF trades at $34.22, while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SCHD | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $150.61 |
52-Week Low | $26.44 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $34.41, down 1.12% over the past day, with technical indicators showing a mixed but overall bullish bias. The ETF's recent dividend announcement for June 2026 highlights its income focus, while news coverage emphasizes its role in retirement portfolios and comparisons with peers like JEPI. Support and resistance levels are tightly clustered around $34-$35, indicating potential for near-term consolidation.
The outlook for SCHD remains favorable for dividend-focused investors, supported by strong inflows and media optimism, though risks include market volatility and competition from other income ETFs. Its low expense ratio and quality screening process continue to attract long-term holders seeking steady income and moderate growth.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
